ISRCTN10640292进行中（未招募）Unknown
Safety and effectiveness clinical evaluation of injectable medical device Hydragel A1 in the skin quality improvement
ouna Aesthetics0 个研究点目标入组 40 人开始时间: 2023年5月2日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Female and male subjects
- •2.Fitzpatrick skin of the face from III to V
- •3. Aged between 18 to 45 years old
- •4. Subjects seeking an improvement in their skin brightness
- •5. Subjects seeking improvement of their skin quality
- •6. Subjects of any phototype and ethnicity
- •7. Subjects who have given their consent for photographs for illustration purposes
- •8. Subjects willing to abstain from other facial aesthetic procedures in the mid-face through the entire study duration
- •9. Subjects in good general and mental health in the opinion of the investigator
- •10. Subjects who have given their free, informed and expressed written consent
- •11. Subjects who have the ability to read and fully understand the aims of the study and its conduct and have given their free, informed and expressed written consent
- •12. Subjects agreeing to cooperate, in full awareness of the study objectives, the necessity and the duration of the follow-up controls at the trial site to ensure perfect adherence to protocol
- •13. Subjects who, in the judgement of the investigator, are likely to be compliant during the study
- •14. Subjects willing and capable of following the study rules and a fixed schedule
- •15. Subjects willing and capable to sign an informed consent document (including the language)
排除标准
- •1. Subject with any systemic disorder or skin disease that would in any way confound the interpretation of the study results
- •2. Subjects with medical/surgical/severe allergy/anaphylactic shock history that, in the opinion of the Investigator, could compromise the safety of the subject or affect the outcome of the study
- •3. Subjects having a known risk of hypersensitivity to one of the components of the composition
- •4. Subjects suffering from autoimmune disease
- •5. Subjects having cutaneous disorders, inflammation or infection (herpes, acne, etc.) at the treatment site or nearby
- •6. Subjects for whom medical history shows a sensitivity that could lead to a reaction to the treatment
- •7. Subjects with bleeding disorders or subjects who are undergoing treatment with thrombolytics or anticoagulants
- •8. Subjects with a tendency to form keloids, hypertrophic scars or any other healing disorders
- •9. Subjects who are currently following a skin treatment
- •10. Pregnant or breastfeeding women or those considering a pregnancy during the study
- •11. Female subjects of childbearing potential with a positive urine pregnancy test (UPT) at D-3-D0
- •12. Subject who has been deprived of their freedom by administrative or legal decision or who is under guardianship
- •13. Subject who cannot be contacted by telephone in case of emergency
- •14. Subject in an exclusion period or participating in another biomedical research study (self-reported)
- •15. Intellectual/mental inability to follow study instructions (if suspected) or incapacitation
研究者
相似试验
进行中（未招募）
Unknown
Evaluation of the injectable medical device Hydragel A2 for skin quality improvementFace skin qualitySkin and Connective Tissue DiseasesISRCTN37981524ouna Aesthetics49
撤回
不适用
Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients with Hypertension: A Double-Blind Randomized Trialhigh blood pressure1000752110057166HypertensionNL-OMON46157BackBeat Medical, Inc.10
招募中
3 期
A clinical study to evaluate the efficacy and safety of the Vamana karma followed with two Rasayanas Takradhara and Rasaoushadi in treatment of psoriasis.CTRI/2016/02/006631Central council for Research in Ayurvedic sciences CCRAS110
已完成
3 期
Evaluation of the Clinical Safety and Efficacy of Suprimun in Renal Transplant RecipientsComparative Interventional Treatment for reduceing the renal transplant rejection.kidney transplant rejectionIRCT2013012612274N1Vice-Chancellor for Research, Shahid Beheshti University of Medical Sciences100
已完成
3 期
Evaluation of the Clinical Safety and Efficacy of Suprimun in Renal Transplant RecipientsComparative Interventional Treatment for reduceing the renal transplant rejection.kidney transplant rejectionIRCT2014072118548N1Research Deputy of Kermanshah University Of Medical Sciences60